Voya Investment Management LLC Cuts Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Voya Investment Management LLC lowered its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 11.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,475 shares of the life sciences company’s stock after selling 2,679 shares during the period. Voya Investment Management LLC’s holdings in Integra LifeSciences were worth $487,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in IART. Arrowstreet Capital Limited Partnership lifted its position in shares of Integra LifeSciences by 7.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock worth $312,000 after buying an additional 913 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 1,371 shares during the period. Sterling Capital Management LLC boosted its position in Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock worth $49,000 after purchasing an additional 1,931 shares during the last quarter. Covestor Ltd increased its position in shares of Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock valued at $123,000 after purchasing an additional 2,071 shares during the last quarter. Finally, MetLife Investment Management LLC raised its stake in shares of Integra LifeSciences by 5.3% during the 4th quarter. MetLife Investment Management LLC now owns 41,749 shares of the life sciences company’s stock worth $947,000 after purchasing an additional 2,111 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on IART shares. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. JPMorgan Chase & Co. decreased their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating for the company in a research note on Tuesday. Wells Fargo & Company dropped their price objective on Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Tuesday. JMP Securities decreased their target price on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a research report on Friday. Finally, Truist Financial cut their price target on Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research note on Friday, April 11th. Four equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and an average price target of $18.63.

Integra LifeSciences Trading Down 5.0 %

Shares of IART opened at $12.25 on Friday. The business’s 50-day moving average price is $18.93 and its 200-day moving average price is $21.87. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a twelve month low of $11.60 and a twelve month high of $32.66. The stock has a market cap of $946.31 million, a PE ratio of -136.10, a P/E/G ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. During the same period in the previous year, the business earned $0.55 earnings per share. The firm’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, equities analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.